Evaluation and management of hypersensitivity reactions to chemotherapy agents

Postgraduate Medical Journal

Volumn 91, Issue 1073, 2015, Pages 145-150

  Tham, Elizabeth Huiwen ^a,b   Cheng, Yew Kuang ^c   Tay, Miah Hiang ^c   Alcasabas, Ana Patricia ^a,b   Pei Chi Shek, Lynette ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GLENEAGLES HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CREMOPHOR; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; IMMUNOGLOBULIN E; OXALIPLATIN; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ANGIONEUROTIC EDEMA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BREAST CANCER; BREAST CARCINOMA; CANCER INCIDENCE; CHEMOTHERAPY; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; DESENSITIZATION; DIAGNOSTIC TEST; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; LUNG CANCER; NAUSEA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PREMEDICATION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SKIN TEST; THROMBOCYTOPENIA; URTICARIA; VASCULITIS; VOMITING; WHEEZING; DOSE RESPONSE; IMMUNOLOGY; PATIENT REFERRAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CISPLATIN; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; REFERRAL AND CONSULTATION; RISK FACTORS; SKIN TESTS; TAXOIDS; TREATMENT OUTCOME;

EID: 84924728262     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2014-132686     Document Type: Article

References (60)

1. Alsamarai S, Charpidou AG, Matthay RA, et al. Pneumonitis related to docetaxel: case report and review of the literature. In Vivo 2009;23:635–7.
2. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005;15:13–18.
3. Basu R, Rajkumar A, Datta NR. Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol 2002;7:365–7.
4. Bautista MA, Stevens WT, Chen CS, et al. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol 2010;3:12.
5. Mertens WC, Eisenhauer EA, Jolivet J, et al. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994;5:185–7.
6. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004–14.
7. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993;4:610–11.
8. Feldweg AM, Lee CW, Matulonis UA, et al. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005;96:824–9.
9. Castells M. Update on mast cells and mast cell precursors and hypersensitivity responses. Allergy Asthma Proc 1997;18:287–92.
10. Szebeni J, Alving CR, Savay S, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1:721–35.
11. Wong JT, Ling M, Patil S, et al. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2014;2:40–5.
12. Garufi C, Vaglio S, Brienza S, et al. Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 2000;11:497.
13. de Vries RS, Mattijssen EJ, van Sorge AA. Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 2006;17:1723–4.
14. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–8.
15. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999;162:8.
16. Peereboom DM, Donehower RC, Eisenhauer EA, et al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993;11:885–90.
17. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001;24:767–79.
18. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:7.
19. Weiszhar Z, Czucz J, Revesz C, et al. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 2012;45:492–8.
20. Prieto Garcia A, Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 2010;20:170–1.
21. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013;68:853–61.
22. Gastaminza G, de la Borbolla JM, Goikoetxea MJ, et al. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 2011;21:108–12.
23. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999;17:1141.
24. Schwartz JR, Bandera C, Bradley A, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecol Oncol 2007;105:3.
25. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24:253–62.
26. Sendo T, Sakai N, Itoh Y, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 2005;56:91–6.
27. Hesterberg PE, Banerji A, Oren E, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009;123:1262–7 e1.
28. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001;19:3126–9.
29. Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611–4.
30. Pagani M, Bonadonna P, Senna GE, et al. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol 2008;145:54–7.
31. Garufi C, Cristaudo A, Vanni B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003;14:497–8.
32. Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002;20:1146–7.
33. Caiado J, Venemalm L, Pereira-Santos MC, et al. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 2013;1:494–500.
34. Leguy-Seguin V, Jolimoy G, Coudert B, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007;119:726–30.
35. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574–80.
36. Simons FE, Ardusso LR, Bilo MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014;7:9.
37. Muraro A, Roberts G, Worm M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 2014;69:1026–45.
38. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393–9.
39. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs 2007;11(1 Suppl):37–42.
40. Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000;18:102–5.
41. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61:129–33.
42. Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378–82.
43. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89:477–81.
44. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996;14:422–8.
45. Gennari A, Salvadori B, Tognoni A, et al. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 1996;7:978–9.
46. Markman M, Kennedy A, Webster K, et al. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol 1997;15:3517.
47. Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002;41:418–24.
48. Chouhan JD, Herrington JD. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration. J Oncol Pharm Pract 2011;17.
49. Syrigou E, Dannos I, Kotteas E, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011;156:320–4.
50. Pagani M, Venemalm L, Bonnadona P, et al. An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem. Jpn J Clin Oncol 2012;42:347–50.
51. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 2005;138:11.
52. Shalit M, Levi-Schaffer F. Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy 1995;25:896–902.
53. Liu A, Fanning L, Chong H, et al. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy 2011;41:1679–89.
54. Fishman A, Gold T, Goldberg A, et al. Effective desensitization protocol to paclitaxe following hypersensitivity reaction. Int J Gynecol Cancer 1999;9:156–9.
55. Essayan DM, Kagey-Sobotka A, Colarusso PJ, et al. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996;97(1 Pt 1):42–6.
56. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;117:7.
57. Rueff F, Przybilla B, Bilo MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009;124:1047–54.
58. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 2009;102:155–60.
59. Joint Task Force on Practice P, American Academy of Allergy A, Immunology, et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010;105:259–73.
60. de Groot H, Mulder WM. Clinical practice: drug desensitization in children. Eur J Pediatr 2010;169:1305–9.